Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira

Restructuring charges impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira
 
2Q Revenues: $1.0 billion (-3%)

2Q Loss: $2.5 million (earnings were $143.6 million 2Q11)

YTD Revenues: $2.0 billion (-3%)

YTD Earnings: $37.8 million (earnings were $293.5 million YTD11)

Comments: Specialty Injectable Pharmaceuticals revenue was $644.2 million (-5%). Medication Management revenue was $255.1 million (+4%). Other Pharma revenues, which includes contract manufacturing services, were down 6% to $134.0 million. Restructuring costs were $32.2 million in the quarter compared to $1.5 million in 2Q11, with facilities optimization charges of $17.4 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters